Design Therapeutics, Inc.

DSGN

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Baker Bros. Advisors Driehaus Capital RA Capital Management

Catalysts

No catalysts tracked.

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 2,233,099Value: $20.9M

**Signal Note: Baker Bros. Initiates Position in Design Therapeutics (DSGN)** The reported position value of ~$20.9B appears to be a data error (DSGN's entire market cap is ~$150-200M); the share count of 2.23M shares likely represents a ~$15-20M position, but Baker Bros. taking any new stake in DSGN is notable given their concentrated, high-conviction approach to biotech. Design Therapeutics is developing small-molecule gene-targeted chimeras (GeneTACs), with lead program DT-216 targeting Friedreich's ataxia — a rare neurodegenerative disease with no approved disease-modifying therapy — where Phase 1 dose-escalation data readouts are the key near-term catalyst. Baker's entry suggests they see a favorable risk/reward ahead of clinical data, consistent with their pattern of

Driehaus CapitalNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

SION3 funds NUVL3 funds EWTX3 funds SYRE3 funds JBIO3 funds RYTM3 funds WVE3 funds PRAX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: Driehaus Capital Initiates Design Therapeutics** Growth-focused Driehaus established an $11.1M position in DSGN, likely reflecting conviction in the company's allele-selective CRISPR platform targeting transcription factor diseases, particularly progranulin (GRN) haploinsufficiency for frontotemporal dementia—a rare indication with limited therapeutics and potential for expedited regulatory pathways. The timing suggests positioning ahead of near-term clinical or partnering catalysts, though DSGN's pipeline stage and capital requirements warrant monitoring given typical biotech execution risks.